Effects of YF476 and Rabeprazole on Gastric Function
Status:
Completed
Trial end date:
2007-06-01
Target enrollment:
Participant gender:
Summary
The primary objectives are to find out in healthy subjects if:
- YF476 prevents the ECL-cell hyperplasia induced by repeated doses of rabeprazole - a
proton pump inhibitor;
- YF476 also prevents rebound hyperacidity after stopping rabeprazole; and
- YF476 by itself causes neither ECL-cell hyperplasia after repeated doses nor rebound
hyperacidity after stopping YF476.
The secondary objectives are to:
- assess the safety and tolerability of YF476, alone and in combination with rabeprazole;
- compare the effects of YF476, alone and in combination with rabeprazole, on serum
gastrin and plasma CgA and SST;
- assess if there is a pharmacokinetic interaction between YF476 and rabeprazole;
- assess the pharmacokinetics of repeat doses of YF476 by itself; and
- study the metabolism of YF476.